A. Rob P.M. Valentijn

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

Gemma G. Kenter, Marij J.P. Welters, A. Rob P.M. Valentijn et al. · New England Journal of Medicine · 2009 · 1.1K citations · Full text

Medicine, Immunology, Oncology +17

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

Marij J.P. Welters, Gemma G. Kenter, Sytse J. Piersma et al. · Clinical Cancer Research · 2008 · 368 citations · Full text

Medicine, Immunology, Oncology +17

Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

Gemma G. Kenter, Marij J.P. Welters, A. Rob P.M. Valentijn et al. · Clinical Cancer Research · 2008 · 309 citations · Full text

Medicine, Immunology, Oncology +17

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

Marij J.P. Welters, Gemma G. Kenter, Peggy J. de Vos van Steenwijk et al. · Proceedings of the National Academy of Sciences · 2010 · 238 citations · Full text

Medicine, Immunology, Oncology +17

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

Mariëtte I.E. van Poelgeest, Marij J.P. Welters, Edith M.G. van Esch et al. · Journal of Translational Medicine · 2013 · 187 citations · Full text

Medicine, Immunology, Oncology +17